Partial
Partially Aligned
Patient Risk:
Info
Summary
The AI response’s two indication/limitation claims are supported by the provided Indications and Usage label excerpts, but the response includes additional non-evaluated information about the product name/generic name and ER release mechanism not supported by the specific label text provided in the prompt.
Category Scores
Accurate Statements
HYSINGLA ER is indicated for the management of severe and persistent pain that requires an opioid analgesic and cannot be adequately treated with alternative options, including immediate-release opioids.
Supported by label excerpt under 1 INDICATIONS AND USAGE.
HYSINGLA ER is not indicated as an as-needed (prn) analgesic.
Supported by label excerpt under 1 INDICATIONS AND USAGE (Limitations of Use): 'HYSINGLA ER is not indicated as an as-needed (prn) analgesic.'
Unsupported Statements
Hysingla ER is the brand name for an extended-release opioid formulation of hydrocodone.
Not directly supported by the provided label excerpts (only general descriptive/model statements were included; no corresponding label citation text was provided for this claim).
The generic name for the ER product is hydrocodone bitartrate.
Not supported by the provided label excerpt text in the prompt beyond the DESCRIPTION header; no explicit mapping statement was provided in the excerpts for this specific claim.
Hysingla ER uses extended-release (ER) technology.
The provided excerpts show 'extended-release tablets' in DESCRIPTION, but the AI claim about 'ER technology' is phrased as a mechanism not explicitly described in the provided label text.
The medication is designed to release hydrocodone slowly over time rather than all at once.
The provided label excerpts do not explicitly state the release behavior as 'slowly over time rather than all at once.'
Generic labeling often appears as hydrocodone bitartrate extended-release tablets or capsules.
Not supported by the provided label excerpts (no regulatory labeling examples/cross-references for generics were provided).
Contradictions
Important Omissions
No evaluation of safety-critical labeling sections (e.g., Boxed Warning, Contraindications, Warnings/Precautions, dosing/administration safety, pregnancy/lactation, pediatric use) despite mentioning only two indication/limitation excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Info
The only label-aligned elements evaluated were indications/limitations; additional non-supported descriptive claims could mislead, but no explicit dosing/safety instructions were provided in the AI response beyond label excerpt framing.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Partially Aligned
Primary Issue
Several descriptive claims about ER release and generic naming were not supported by the specific prescribing information excerpts provided.
Suggested Improvement
Restrict statements to what is explicitly present in the provided label text or include the missing label sections/citations needed to substantiate release-mechanism and naming-related claims.